Concert Pharmaceuticals, Inc. Announces Issuance of U.S. Patent for Its Lead Drug Candidate CTP-499  
10/22/2012 9:17:29 AM

LEXINGTON, Mass.--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. today announced that it has been granted U.S. Patent No. 8,263,601 which covers CTP-499, the company’s lead drug candidate in development for the treatment of diabetic nephropathy, a form of chronic kidney disease (CKD). This patent claims the composition of matter and pharmaceutical compositions of CTP-499, which is currently in Phase 2 clinical testing. “We are very pleased to obtain this patent for our lead clinical candidate. This follows patent protection we recently received for several of our priority programs,” said Robert Silverman, Senior Vice President and General Counsel. “We have now used our DCE Platform® to make a wide range of substantially differentiated agents which are covered by a worldwide patent estate that includes 26 issued U.S. patents.”